<DOC>
	<DOCNO>NCT01912222</DOCNO>
	<brief_summary>This phase 1 , 2-part , pharmacokinetic study patient advance solid tumor hematologic malignancy vary degree liver dysfunction ( normal function , moderate hepatic impairement severe hepatic impairment ) define National Cancer Institute ( NCI ) Organ Dysfunction Working Group .</brief_summary>
	<brief_title>Pharmacokinetic Study Oral IXAZOMIB Cancer Patients With Liver Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>18 year old Patients must diagnosis advanced malignant solid tumor hematologic malignancy standard , curative , lifeprolonging treatment exist longer effective Total bilirubin aspartate aminotransferase ( AST ) level consistent normal hepatic function ( total bilirubin AST â‰¤ upper limit normal ) , moderate hepatic impairment ( total bilirubin &gt; 1.5 3x upper limit normal AST level ) severe hepatic impairment ( total bilirubin &gt; 3x upper limit normal AST level ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Female patient postmenopausal least 1 year OR surgically sterile OR childbearing potential , agree practice 2 effective method contraception time entire study 90 day last dose study drug OR agree practice true abstinence Male patient agree practice effective barrier contraception entire study 90 day last dose study drug OR agree practice true abstinence Voluntary write consent Suitable venous access conduct blood sample Appropriate clinical laboratory value specify protocol Systemic treatment strong moderate inhibitor CYP1A2 , strong moderate inhibitor CYP3A , clinically significant CYP3A inducer use Ginkgo biloba St. John 's wort within 14 day first dose study drug Use nicotinecontaining product within 14 day first dose study drug Central Nervous System Involvement Symptomatic brain metastasis . Patients brain metastasis : must stable neurologic status follow local therapy ( surgery radiation ) least 2 week completion definitive therapy ; must without neurologic dysfunction would confound evaluation neurologic AEs Female patient lactate breastfeed positive serum pregnancy test Serious medical psychiatric illness could interfere participation study Treatment investigational product radiotherapy within 21 day first dose study drug Systemic anticancer therapy within 14 day first dose study drug Exposure nitrosoureas mitomycin C within 6 week first dose study drug Treatment therapeutic monoclonal antibody antibodydrug conjugate within 60 day first dose study drug Radiotherapy major surgery within 14 day precede first dose study drug Infection require systemic intravenous antibiotic therapy serious infection within 14 day first dose study drug Lifethreatening illness unrelated cancer Severe CNS , pulmonary , renal disease relate patient 's cancer Known human immunodeficiency virus ( HIV ) positive Evidence uncontrolled cardiovascular condition QTc &gt; 500 millisecond ( msec ) 12lead ECG obtain Screening period Known GI disease GI procedure could interfere oral absorption tolerance IXAZOMIB Known allergy study medication , analogue , excipients formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>